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Background: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Tumor control
and survival have improved with the use of radiotherapy (RT) plus concomitant and adjuvant chemotherapy, but
the prognosis remain poor. In most cases the recurrence occurs within 7–9 months after primary treatment.
Currently, many approaches are available for the salvage treatment of patients with recurrent GBM, including
resection, re-irradiation or systemic agents, but no standard of care exists.
Methods: We analysed a cohort of patients with recurrent GBM treated with frame-less hypofractionated
stereotactic radiation therapy with a total dose of 25 Gy in 5 fractions.
Results: Of 91 consecutive patients with newly diagnosed GBM treated between 2007 and 2012 with conventional
adjuvant chemo-radiation therapy, 15 underwent salvage RT at recurrence. The median time interval between
primary RT and salvage RT was 10.8 months (range, 6–54 months). Overall, patients undergoing salvage RT showed
a longer survival, with a median survival of 33 vs. 9.9 months (p= 0.00149). Median overall survival (OS) from salvage
RT was 9.5 months. No patients demonstrated clinically significant acute morbidity, and all patients were able to
complete the prescribed radiation therapy without interruption.
Conclusion: Our results suggest that hypofractionated stereotactic radiation therapy is effective and safe in
recurrent GBM. However, until prospective randomized trials will confirm these results, the decision for salvage
treatment should remain individual and based on a multidisciplinary evaluation of each patient.
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The current standard of care for glioblastoma (GBM) is
concurrent Temozolomide (TMZ) and conventional radio-
therapy followed by 6 maintenance cycles of adjuvant
TMZ. Despite standard of care therapy, recurrence rates
remain high (>90%) with a median overall survival (OS) of
15–18 months [1].
In recent years a lot of mono-therapy or combination
chemotherapeutic strategies have been evaluated in pa-
tients with recurrent or progressive GBM. The alkylant* Correspondence: patrizia.ciammella@asmn.re.it
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distribution, and reproduction in any mediumagents (nitrosoureas, procarbazine), used in the past as
first-line treatment, are used today as second-line ther-
apy for recurrence or progression. Overall, the 6-months
progression-free survival (PFS) and median OS with
second-line therapy with alkylant agents ranged from 13
to 24% and from 5 to 11 months, respectively [2-8]. Nu-
merous trials have evaluated the efficacy and safety of
TMZ as a monotherapy for recurrent GBM in patients
previously treated with chemotherapy, mostly nitrosurea-
based [9-15]. Some recent studies evaluated in TMZ-
pretreated patients a second-line TMZ based therapy
[16-21]. In one of these studies, the TMZ resulted more ef-
ficacious than procarbazine (PFS at 6 months= 21% vs 8%)
[16]. Six recent trials of TMZ-pretreated patients evaluated
TMZ re-challenge [17-21]. Unfortunately, considering thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the wide range of TMZ regimen tested, there was no evi-
dence that one regimen was advantageous over another,
and despite some improvements in PFS none of them was
associated with a better survival. The repeated surgery is
feasible only in few cases of recurrent GBM and is not
recommended for patients with involvement of pre-
specified eloquent/critical brain regions [22]. The data re-
lated to reoperation have been derived from retrospective
studies, but it is known that positive prognostic factors of
reoperation for recurrent GBM are a younger age (≤70
years), a smaller tumor volume (≤50 cm3) and pre-
operative KPS greater than 80% [22,23].
Today, for recurrent GBM the re-irradiation remains a
palliative option for a selected group of patients, i.e. those
with a KPS greater than 60%, a tumor size of up to 40
mm, and a time to progression from the surgery of at least
6 months [24]. Usually, a stereotactic radiotherapy tech-
nique is applied [25], but the fractionation schedule and
the prescribed total dose are various and no randomized
trials are available. Both single-fraction stereotactic radio-
surgery (SRS) and fractionated stereotactic radiotherapy
(FSRT) have been reported to have minimal toxicity, with
median survivals of 6–10 months after SRS [26-30] or
FSRT [31-33]. Recently, some studies also have evaluated
the safety and efficacy of the combination of fractionated
RT and concurrent chemotherapy in recurrent high-grade
gliomas showing a median OS and PFS from re-
irradiation of 8–13 and 5–8 months, respectively [34-37].
Our retrospective analysis focused on the efficacy and
toxicity of a hypofractionated stereotactic radiotherapy
for recurrent GBM in a cohort of patients previously
treated with standard therapy.
Methods and materials
This is a retrospective study of efficacy and safety of
hypofractionated stereotactic radiation therapy (SRT) deliv-
ered at 5 fractions of 5 Gy each for management of recur-
rent intracranial GBM. All patients previously underwent a
conventional adjuvant chemo-radiation therapy according
to Stupp protocol after a maximal surgical resection for a
newly diagnosed GBM. The histopathological diagnosis of
primary GBM was established according to the current
World Health Organization Criteria [38].
The protocol was approved by the local Ethics commit-
tee and informed consent was obtained for all patients.
Recurrence definition
The diagnosis of tumor recurrence was based on the
joint opinion of the neuro-radiologist, neurosurgeon, ra-
diation oncologist and neuro-oncologist, and was de-
fined as appearance of new contrast-enhanced lesion(s)
on T1-weichted MRI or an increase of 25% or more of
the volume of the initial enhanced lesion(s). In case ofdoubt between tumor recurrence and pseudo-progression
a MR imaging was repeated after one month. Recurrences
were defined, as suggested by Lee et at [39], as “ in-field”
if > 80% of the tumour recurrence resided within the pre-
scription 95% isodose surface, and “marginal” if 20% to
80% of the lesion was inside the 95% isodose surface. In all
other cases, recurrences were defined as outside of the ra-
diation field. At the time of recurrence, all patients were
evaluated for salvage treatment, which included re-
resection of the tumor, hypo-fractionated radiation ther-
apy, chemotherapy, or combined approaches.
Re-irradiation protocol
The indication for re-irradiation at tumor recurrence
was evaluated by the interdisciplinary neuro-oncology
team and based on: the patient clinical condition (i.e.
KPS> 60), the lesion location and the spread of disease
(patients with multifocal spread of disease were ex-
cluded). All patients undergoing re-irradiation were
immobilized in customized thermoplastic shells for CT
and MR simulation. The GTV was delineated on the
basis of the contrast-enhancing tumor on T1-weighted
MRI registered with CT images. For the image registra-
tion an automatic fusion algorithm was used; anyway the
resulted registration was subsequently checked by mean
of anatomic markers and, if needed, manually adjusted.
The PTV was generated by applying to GTV an isotropic
expansion of 3–5 mm. The critical structures and previ-
ously high dose irradiated volumes were contoured. All
patients were treated with hypo-fractionated stereotactic
radiation therapy with multiple no-coplanar beams using
on a standard 6-MV linear accelerator (LINAC). A total
dose of 25 Gy prescribed to the 70% isodose line and de-
livered in 5 consecutive fractions was delivered. A daily
pre-treatment verification with orthogonal fields was
performed.
Follow-up protocol
All patients were evaluated at four weeks, 12 weeks and
once every 3 months after the salvage treatment. The
work-up included history and physical examination (with
particular regard to KPS, neurological status and toxicity
assessment), blood tests and contrast-enhanced brain
MRI. No specific quality-of-life questionnaire was ad-
ministered. Haematologic and no-haematological toxic-
ities were graded according to Common Terminology
Criteria for Adverse Events. Other investigations were
not performed unless were clinically indicated.
Statistical analysis
Statistical analysis were performed using the R statistical
software (http://www.R-project.org), particularly the sur-
vival package. Patient characteristics were compared
with Fisher-test and a twosided significance level was
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Kaplan-Meier method. The p-values estimated are those
for a two tailed test and the significance level was chosen
to be 5%. Cox regression analysis was used for univariate
analysis and parameters were tested for proportionally and
categorical covariates compared by log-rank test. A multi-
variate Cox proportional hazards analysis was used to
evaluate prognostic factors and treatment with respect to
the overall survival from initial diagnosis and from time of
recurrence. Variables included in the model were selected
when statistically significant in univariate analysis. Data
are presented as 1-mont actuarial hazard ratios (HR) with
95% confidence intervals, unless otherwise mentioned.
Results
Between 2007 and 2012 we treated with standard chemo-
radiation therapy according to Stupp protocol 91 patients
with newly diagnosed GBM. With mean follow-up of 13.9
months (range 1–63 months), the median OS was 15
months, with a PFS of 9 months. In this populations of pa-
tients, the age (≤65 years), extent of resection, KPS, RPA
class and O6-methylguanine-DNA-methyltransferase
(MGMT) methylation were significantly associated
with OS.
The pattern of recurrences was analysed in 83 patients
who had recurrences. Recurrence occurred “in-field” in 61
patients (73%), at RT field margin in 7 patients (9%) and
“out-field” in 15 patients (18%). No patients had CSF/
spinal or distant disease recurrence. No correlation be-
tween extent of surgery and site of relapse was seen
(>0.05). Progression-free survival did not differ signifi-
cantly between patients with regional or marginal progres-
sion and patients with distant recurrences. Comparison of
the investigated clinical factors did not differ significantly
between the two groups (“in-field” vs “out-field”). No cor-
relation between tumor location, tumor side, extent of pri-
mary surgery and pattern of recurrence was found.
At the time of recurrence, re-surgery was performed in
6 patients and second line chemotherapy in 37 patients.
The salvage re-irradiation was performed in 9 of 58 pa-
tients with regional or marginal tumor progression and in
6 of 13 patients with distant recurrence. The remaining
patients with tumor recurrence not eligible for salvage
therapies (due to old age, poor performance status, severe
comorbidities, patient choice) have received best support-
ive care. Table 1 shows the comparison between the differ-
ent types of approaches for recurrent GBM (re-irradiation,
re-surgery, second-line chemotherapy and best supportive
care) in terms of patients’ characteristics and clinical out-
comes. The median time interval between primary RT and
re-irradiation was 10.8 months (range, 6–54 months). No
patients demonstrated clinically significant acute morbid-
ity, and all patients were able to complete the prescribed
treatment without interruption. No patient requiredhospitalization or surgery for early acute or delayed tox-
icity. Neurological deterioration occurred in two patients
at 1 and 3 months after re-irradiation and was managed
successfully with dexamethasone. Log-rank test revealed
that the patients undergoing re-irradiation showed a lon-
ger survival compared to those treated with best support-
ive care, with a median overall survival from primary
GBM diagnosis of 33 vs 9.9 months (p= 0.0015). As well
the patients treated with re-surgery or second line chemo-
therapy showed a longer survival than untreated patients,
with a median OS from diagnosis of 17 months. The me-
dian time of recurrence from primary GBM diagnosis was
statistically significant higher in the re-irradiation group
when compared to all patients (19 months, 10 months, 8
months and 5 months in RT, surgery, chemotherapy and
best supportive care, respectively, p= 0.00003). This find-
ing may explain the higher overall survival of patients
undergoing re-irradiation. The median survival from re-
currence was 9.5 months, 5.5 months and 2.5 months for
RT, chemotherapy and best supportive care group, re-
spectively. This difference was statistically significant be-
tween RT and best supportive care group (p= 0.000001),
between chemotherapy and best supportive care group
(p= 0.00007) and between RT and second-line chemother-
apy group (p=0.049). The Figures 1 and 2 show the
Kaplan-Meier curves for OS from primary GBM diagnosis
and from recurrence, comparing those treated with RT,
surgery, chemotherapy and best supportive care.
The clinical characteristics of the patients in the four
treatment groups were similar, except for the median age
that was significantly lower in the RT group (p<0.05). The
patients who underwent re-irradiation and re-surgery
showed better clinical conditions (KPS) compared with
patients treated with second-line chemotherapy or un-
treated (best supportive care), but the difference did not
reach statistical significance.
In all re-treated patients, the multivariate Cox pro-
portional hazard analysis confirmed the negative prog-
nostic effect of the older age [hazard ratio (HR): 4.1
(95%CI: 1.5 -10.3), p=0.005] and the biopsy alone [HR:
4.5 (95%CI: 1.4–14.4), p= 0.011] on the OS. No correl-
ation was found between the other analysed factors
(sex, MGMT methylation, RPA class, primary tumor
side, primary tumor volume, KPS at diagnosis and KPS
at recurrence) and OS. In all recurrent patients there
was no correlation between OS from recurrence and
type of recurrence ("in-field" or "out -field"), though in
the group of re-irradiated patients with “in-field” pro-
gression had a mild tendency to better OS comparing
with patients with “out-field”. Surprisingly, in the re-
irradiated group, the age alone (with cut-off of 60
years) showed a correlation with OS [HR: 11.92 (95%
CI: 1.1-135), p=0.0045]. None of the others assessed
factors reached statistical significance.
Table 1 Comparison of clinical factors and outcome variables in patients with recurrent glioblastoma treated with
different approaches
Salvage treatment
Characteristics Re-irradiation Re-surgery Chemotherapy Best supportive care p Value
(N= 15) (N=6 ) (N=37 ) (N=25 )
Age (years)
Median 51.5 65 66 66 RT vs no-RT 0.002
Range 41-73 55-73 49-72 55-79
<60 years 5 3 21 20
<=60 years 10 3 16 5 0.02
Gender, N0. (%)
Men 11 (73%) 4 (67%) 22 (59%) 9 (38%) 0.33
Women 4 (27%) 2 (33%) 15 (41%) 16 (62%)
Primary Surgery, N0. (%)
Total 11 (73%) 4 (67%) 18 (49%) 10 (39%) 0.18
Subtotal 3 (20%) 2 (33%) 11 (30%) 4 (15%)
Biopsy 1 (7%) 0 8 (21%) 11 (46%)
Karnofsky performance status at diagnosis (%) .
Median 90 90 90 90 n.s
Range 80-100 80-100 70-100 70-100
RPA classification at diagnosis, N0. (%)
IV 9 (60%) 5 (83%) 18 (50%) 13 (54%)
V 5 (33%) 1 (17%) 8 (20%) 6 (23%)
VI 1 (7%) 0 11 (30%) 6 (23%)
MGMT Methylation, N0. (%)
Yes 7 (47%) 4 (67%) 12 (33%) 10 (38%) 0.47
No 5 (33%) 2 (33%) 20 (54%) 13 (54%)
Unknown 3 (20%) 0 5 (13%) 2 (8%)
Primary Tumor location, N0 (%)
Frontal 3 (20%) 3 (50%) 12 (34%) 10 (39%) 0.72
Temporal 4 (27%) 3 (50%) 13 (35%) 6 (23%)
Parietal 6 (40%) 0 8 (21%) 6 (23%)
Occipital 2 (13%) 0 4 (10%) 3 (15%)
Primary Tumor side, N0 (%)
Left 8 (53%) 4 (67%) 20 (54%) 14 (54%) 0.96
Right 7 (47%) 2 (33%) 17 (46%) 11 (46%)
Type of recurrence, N0 (%)
In-field 9 (60%) 5 (83%) 32 (86%) 19 (77%)
Out-field 6 (40%) 1 (17%) 5 (14%) 6 (23%) 0.19
Karnofsky performance status at recurrence (%)
Median 90 90 80 80 n.s.
Range 80-100 80-100 70-100 70-100
Median OS from primary diagnosis (months) 33 17 17 9.9 RT vs no-RT 0.001
Cox regression analysis OR coef f-p 0.102 0.268 0.331 1
1.4e-07 0.016 0.00018 -
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Table 1 Comparison of clinical factors and outcome variables in patients with recurrent glioblastoma treated with
different approaches (Continued)
Time between primary therapy and salvage treatment
Median (months) 10.8 10 8 5 0.003
Range (months) 6-54 7-24 7-21 2-11
Median OS from recurrence(months) 9.5 5.5 5.5 2.5 RT vs no-RT 0.001
Cox regression analysisOR coef f-p 0.16 0.34 0.33 1
0.000016 0.052 0.0015 -
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This retrospective study reports the results of a series
of patients affected by GBM treated with conventional
chemo-radiation therapy ad diagnosis and who underwent
various salvage treatment for their tumor recurrence. The
principal focus of our analysis is to evaluate the feasibility
and safety of re-irradiation at tumor progression in pa-
tients previously irradiated. It is well known that the
tumor control and survival in patients with GBM have
been improved by the use of radiotherapy plus concomi-
tant and adjuvant TMZ. Unfortunately, the prognosis re-
main poor with very few long-term survivors. In most
cases the recurrence occurs within 7–9 months from ini-
tial diagnosis [40-42]. Up to 90% of all GBMs relapse in
close proximity to the resection cavity or to the target vol-
ume of postoperative radiotherapy [43,44]. Currently,
many approaches are available for the salvage treat-
ment of patients with recurrent GBM after initial
chemo-radiation therapy, including resection, re-
irradiation or systemic agents, but no standard of careFigure 1 Kaplan-Meier analysis of overall survival from the time
of initial diagnosis in patients with recurrent GBM treated with
radiotherapy (RT), surgery (Sur), chemotherapy (CT) or best
supportive care.exists. Chemotherapy is the most common treatment
option for recurrent GBM, but it is associated, when
administered alone, with poor OS ( 4–6 months) [41].
The drugs commonly used in the treatment of these
patients are many (TMZ, carboplatin, procarbazine,
bevacizumab and imatinib) administered as single-
agent or in combination. Recent series reported prom-
ising results with TMZ alone with a 6 months PFS of
30% [13]. The use of Bevacizumab was approved by the
US Food and Drug Administration because of some phase
II trials indicating prolonged 6-month PFS and OS [45].
Several studies suggest that a more aggressive approach
with gross total resection and/or high dose re-irradiation
may result in improvement of local control of recurrent
GBM. A recent review reported an OS of 3–11 months in
patients with recurrent GBM treated with surgery [23].
Young et al. [46] reported in 24 patients with tumor recur-
rence treated with surgery alone an OS of 3.3 months.
With a combination of re-intervention and chemotherapy,
an increase of PFS and OS was reported [47].Figure 2 Kaplan-Meier analysis of overall survival from the time
of recurrence in patients with recurrent GBM treated with
radiotherapy (RT), surgery (Sur), chemotherapy (CT) or best
supportive care.
Table 2 Survey of clinical outcomes after re-irradiation: fractionated stereotactic radiation therapy (FSRT), radiosurgery (SRS), brachytherapy (BT) of recurrent
GBM
Authors Patients (n) Type of RT Total dose/fractions Outcomes from the re-irradiation
Cho et al. [30] 25 FSRT Median dose of 37.5 Gy (range, 20-45 Gy) /2.5 Gy fractions (range, 1.8-3 Gy) Median survival 12 months
Cho et al. [30] 46 SRS Median total dose of 17 Gy delivered to the median of 50% isodose surface Median survival 11 months
Combs et al. [31] 59 FSRT 36 Gy/2 Gy fractions Median OS 8 months
1-year survival rates 23%
Median PFS 5 months
1-year PFS 5%
Vordermark et al. [33] 19 FSRT Median total dose 30 Gy (range, 20–30 Gy) /5 Gy fractions (range, 4–10 Gy) Median OS 7.9 months
Simon et al. [49] 42 Iridium BT 50 Gy Median OS 12.5 months
Chan et al. [50] 24 BT 53 Gy Median OS 9.1 months
Larson et al. [51] 14 SRS 15 Gy/1 fraction Median OS 9.5 months
Combs et al. [32] 32 SRS 15 Gy/1 fraction Median OS 10 months
Shrieve et al. [52] 86 SRS 13 Gy/1 fraction Median OS 10.2 months
Shrieve et al. [52] 32 BT 50 Gy Median OS 11.5 months
Grosu et al. [53] 33 FSRT 30 Gy Median OS 8 months (for astrocytomas
and gliomas)
Kohshi et al. [54] 25 FSRT 22 Gy Median OS 11 months
Ernst-Stecken et al. [55] 15 FSRT 35 Gy/7 Gy fractions 6 months PFS 75%
12 months PFS 53%
Fokas et al. [56] 53 FSRT Median dose 30 Gy (range 20-60 Gy)/ 3 Gy fractions (range 2-5 Gy) Median OS 9 months
1-year PFS 22%
2-year PFS 5%
Henke et al. [57] 31 (2 grade III, 29 grade IV) FSRT Median total dose 20Gy (range, 20–25)/ 5 Gy fractions Median OS 10.2 months,
Fogh et al. [58] 147 (42 grade III, 105 grade IV) FSRT Median dose 35 Gy in 3.5-Gy fractions Median OS 11 months for grade III and 8
months for grade IV
Shepherd et al. [59] 29 FSRT Median dose 35 Gy (range, 20–50 Gy)/ 5 Gy fractions Median OS 10.7 months
Glass et al. [60] 20 (7 grade III, 13 grade IV) FSRT Median dose 38 Gy (range, 35–42 Gy)/ 3.5–6 Gy fractions Median OS 12.7 months
Hudes et al. [61] 19 FSRT Median dose 30 Gy (range, 24–35 Gy)/ 3–3.5 Gy fractions Median OS 10.5 months
Lederman et al. [34] 88 FSRT Total dose 18–36/ 4–9 Gy (weekly) Median OS 7 months
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interest in fractionated stereotactic radiation therapy as
a palliative treatment of recurrent GBM.
Combs et al. reported a median OS after re-irradiation
of 8 months by applying normo-fractionated stereotactic
radiotherapy [32]. The same authors have found an OS of
10 months in patients undergoing single-fraction stereo-
tactic radiosurgery for recurrent GBM [28]. Vordermark
et al. [33] showed a median OS of 7.9 months after hypo-
fractionated stereotactic radiation therapy in 19 patients
with recurrent GBM. Sirin et al. reported an overall sur-
vival from recurrence of 9.3 months after radiosurgery for
recurrent GBM [48]. Similar results have been reported by
other studies summarized in Table 2 [30-34,49-63]. But a
comparison of clinical outcomes provided by the applica-
tion of so many and different approaches of re-irradiation
certainly remains difficult because of the variation in tar-
get definition, treatment technique, total dose and dose/
fractions, in the introduction of concomitant chemother-
apy and initial patient characteristics.
A recent review has analysed data from more than 300
GBM patients and has demonstrated that re-irradiation
yields an increase of the 6-month PFS, that moves from
28% to 39% and 1-year overall survival of 18% to 48%,
without additional chemotherapy [64]. A clinical im-
provement was observed in 24% to 45% of the cases with
patients with KPS <70 apparently having lesser benefit
from re-irradiation. Recently particular attention re-
ceived the combination of stereotactic radiation therapy
and TMZ in recurrent GBM. The use of TMZ in
addition to radiotherapy was based on the observation
that concurrent chemotherapy can potentiate the cyto-
toxicity of radiation. In a series of 25 patients with re-
current GBM treated at dose of 36 Gy in 2-Gy fractions
in combination with TMZ, the reported median OS and
PFS from re-irradiation were 8 and 5 months, respect-
ively [36]. Grosu et al. reported a median survival time
of 11 months for patients who have received fractionated
stereotactic radiation therapy plus TMZ, while a survival
time of 6 months was reached by patients treated with
fractionated stereotactic radiation therapy without TMZ
(p=0.0008) [53]. Literature is sparse regarding the tox-
icity of hypo-fractionated stereotactic radiotherapy in re-
current GBM. Some studies reported higher rates of
necrosis but because of the wide range of delivered doses
the data are inconclusive. However, the comparison of dif-
ferent studies of re-irradiation remains difficult because of
the variability in target definition, treatment technique,
fractionation schema, use of concomitant chemotherapy
and initial patient characteristics. In the management of
GB, the pattern of failure is one of the major concerns in
relation to the clinical target volume margins, optimal ra-
diation dose, and identification of biomarkers. In the ma-
jority of reported series, local progression after initialmanagement was encountered in 60% to 97% of cases, but
comparison of different studies is difficult due to differ-
ences in treatment strategy, extension of surgical removal,
postoperative surveillance, length of follow up as well as
definition and categorization of the tumor progression.
Several studies have shown that the majority of pa-
tients with GBM treated with RT plus concomitant
and adjuvant temozolomide have central recurrences
[65-68]. Furthermore, many previous trials found that
the type of local recurrence in relation to the radiation
fields (“in field”, “marginal” or “out-field” recurrence)
was associated with impaired prognosis [68-73]. In
particular, the median survival was 17.3, 14.8 and 26.1
months in patients with recurrence inside, at the mar-
gin and outside the irradiation field [71].
The objective of the current study is to evaluate retro-
spectively the efficacy and the safety of the re-irradiation
of patients with recurrent GBM in comparison with
other salvage approaches. The patients of the study were
part of a consecutive series of 91 patients previously
treated with standard RT and TMZ.
In our series the pattern of recurrences evaluated in 71
cases was : “in-field” recurrence in 51 patients (73%), mar-
ginal recurrence in 7 patients (9%) and “out-of-field” re-
currence in 13 patients (17%). At tumor recurrence/
progression, only 15 and 6 patients received a salvage radi-
ation treatment or a re-operation, respectively. The
remaining 50 patients with disease progression had been
considered un-fit for local therapy and received a second
line chemotherapy (37 patients) or the best supportive
care (13 patients). The median survival time after diagno-
sis of tumor recurrence in the group of patients treated
with re-irradiation (9.5 months) was significantly longer
than that who received best supportive care (2.5 months,
p=0.0001) and which has had a longer trend compared to
that of patients treated with chemotherapy of second line
(5.5 months, p=0.049). Furthermore, we have found that
patients treated with re-irradiation at the time of tumor
recurrence has had the longest overall survival from the
time of initial diagnosis (33 months, p=0.000049). How-
ever, we can not exclude that this finding may result from
selection bias for application of the different types of sal-
vage treatment. Also the patients who underwent re-
surgery show to survive less than re-irradiated patients
(median OS 33 vs 17 months respectively, p= 0.00034).
We did not found a significant correlation between the
OS and the pattern of failure, although in the group of pa-
tients with “in-field” rather than outside progression a
mild tendency to a better OS was observed.. This trend
might reflect an other selection bias, due to the possible
inclusion of some cases of pseudo-progression erroneously
interpreted as local recurrence.
With regard to the time interval between the first to the
second irradiation, we found a positive but not significant
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irradiation.
Unfortunately, our study represents a retrospective ana-
lysis and patients at the time of tumor recurrence were
not randomized to one or the other salvage treatment. In
addition, the indication for the salvage treatment and the
choice of which perform (surgery, re-irradiation, chemo-
therapy) was evaluated by our interdisciplinary neuro-
oncology team (and from the patient preferences too).
The clinical and tumoral features that have guided their
decision were mainly: the patient clinical condition (i.e.
KPS> 70), the lesion location and the spread of disease.
This means that patients with up-front worse prognosis
were excluded from the re-irradiation. Stratifying for these
characteristics, the analysis of all patients showed no dif-
ferences between the groups of different salvage strategies
and did not allow the identification of factors associated
with choice of one or other salvage treatment. On the
basis of these considerations, it was not possible to match
the patients included in these groups and therefore the
drawing of any conclusions regarding the efficacy of each
treatment modality it can suffer of some bias and/or
arbitrary.
On the other hand, our results confirm the feasibility
and safety of re-irradiation in recurrent GBM. In fact, in
our population, although it is a small series, re-irradiation
was not accompanied by any case of significant morbidity
or side effect. Literature is sparse regarding the toxicity of
hypo-fractionated stereotactic radiotherapy in recurrent
GBM. Previous studies reported higher rates of necrosis
but have utilized a wide range of doses. An association has
been noted between higher rates of re-operation and doses
greater than 40 Gy [59,74]. With the limitations of the
data now at our disposal, radiation therapy for recurrent
GBM after standard therapy seems to be safe and in our
study the re-irradiated patients have a longer OS com-
pared to patients treated with other approaches.
Conclusion
Our study shows that hypo-fractionated stereotactic ra-
diation therapy is effective and safe in recurrent GBM
after conventional chemo-radiation treatment, even if
the dose response and dose limits remain unclear. Any-
way, until prospective randomized trials will confirm
these results, the decisions for salvage re-irradiation
should be based on multidisciplinary evaluation and
personalized on the patient.
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